Abacavir/lamivudine combination in the treatment of HIV: a review
Geetha Sivasubramanian1, Emmanuel Frempong-Manso2, Rodger D MacArthur11Division of Infectious Diseases, Wayne State University, Detroit, MI, USA; 2University of Pittsburgh Medical Center, Shadyside Hospital, Pittsburgh, OH, USAAbstract: Abacavir has been at the center of research and clinical intere...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2010-02-01
|
| Series: | Therapeutics and Clinical Risk Management |
| Online Access: | http://www.dovepress.com/abacavirlamivudine-combination-in-the-treatment-of-hiv-a-review-a4006 |
| _version_ | 1828141267661357056 |
|---|---|
| author | Geetha Sivasubramanian Emmanuel Frempong-Manso Rodger D MacArthur |
| author_facet | Geetha Sivasubramanian Emmanuel Frempong-Manso Rodger D MacArthur |
| author_sort | Geetha Sivasubramanian |
| collection | DOAJ |
| description | Geetha Sivasubramanian1, Emmanuel Frempong-Manso2, Rodger D MacArthur11Division of Infectious Diseases, Wayne State University, Detroit, MI, USA; 2University of Pittsburgh Medical Center, Shadyside Hospital, Pittsburgh, OH, USAAbstract: Abacavir has been at the center of research and clinical interest in the last two years. The frequency of the associated abacavir hypersensitivity syndrome has decreased substantially since the introduction of routine testing for the HLA-B*5701 allele; the activity of the drug in HIV-infected persons with HIV RNA values more than 100,000 copies/mL has been questioned; the possible increased risk of myocardial infarction after recent exposure to abacavir has been debated; and the drug has been moved from the “recommended” category to the “alternative” category in several guidelines. Still, the drug remains a useful agent in combination with other drugs, including lamivudine, for the treatment of HIV infection. This review will focus on the pharmacokinetics, activity, side effects, and resistance profile of both abacavir and lamivudine, including a thorough review of all of the recent studies relevant to both drugs.Keywords: HIV, abacavir, lamivudine |
| first_indexed | 2024-04-11T19:21:32Z |
| format | Article |
| id | doaj.art-e4e5c5cc985249b6a5cc6d038ab23378 |
| institution | Directory Open Access Journal |
| issn | 1176-6336 1178-203X |
| language | English |
| last_indexed | 2024-04-11T19:21:32Z |
| publishDate | 2010-02-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Therapeutics and Clinical Risk Management |
| spelling | doaj.art-e4e5c5cc985249b6a5cc6d038ab233782022-12-22T04:07:17ZengDove Medical PressTherapeutics and Clinical Risk Management1176-63361178-203X2010-02-012010default8394Abacavir/lamivudine combination in the treatment of HIV: a reviewGeetha SivasubramanianEmmanuel Frempong-MansoRodger D MacArthurGeetha Sivasubramanian1, Emmanuel Frempong-Manso2, Rodger D MacArthur11Division of Infectious Diseases, Wayne State University, Detroit, MI, USA; 2University of Pittsburgh Medical Center, Shadyside Hospital, Pittsburgh, OH, USAAbstract: Abacavir has been at the center of research and clinical interest in the last two years. The frequency of the associated abacavir hypersensitivity syndrome has decreased substantially since the introduction of routine testing for the HLA-B*5701 allele; the activity of the drug in HIV-infected persons with HIV RNA values more than 100,000 copies/mL has been questioned; the possible increased risk of myocardial infarction after recent exposure to abacavir has been debated; and the drug has been moved from the “recommended” category to the “alternative” category in several guidelines. Still, the drug remains a useful agent in combination with other drugs, including lamivudine, for the treatment of HIV infection. This review will focus on the pharmacokinetics, activity, side effects, and resistance profile of both abacavir and lamivudine, including a thorough review of all of the recent studies relevant to both drugs.Keywords: HIV, abacavir, lamivudinehttp://www.dovepress.com/abacavirlamivudine-combination-in-the-treatment-of-hiv-a-review-a4006 |
| spellingShingle | Geetha Sivasubramanian Emmanuel Frempong-Manso Rodger D MacArthur Abacavir/lamivudine combination in the treatment of HIV: a review Therapeutics and Clinical Risk Management |
| title | Abacavir/lamivudine combination in the treatment of HIV: a review |
| title_full | Abacavir/lamivudine combination in the treatment of HIV: a review |
| title_fullStr | Abacavir/lamivudine combination in the treatment of HIV: a review |
| title_full_unstemmed | Abacavir/lamivudine combination in the treatment of HIV: a review |
| title_short | Abacavir/lamivudine combination in the treatment of HIV: a review |
| title_sort | abacavir lamivudine combination in the treatment of hiv a review |
| url | http://www.dovepress.com/abacavirlamivudine-combination-in-the-treatment-of-hiv-a-review-a4006 |
| work_keys_str_mv | AT geethasivasubramanian abacavirlamivudinecombinationinthetreatmentofhivareview AT emmanuelfrempongmanso abacavirlamivudinecombinationinthetreatmentofhivareview AT rodgerdmacarthur abacavirlamivudinecombinationinthetreatmentofhivareview |